German Myasthenia gravis registry - research in treatment of patients with myasthenic syndromes in clinical practice
Recruiting
- Conditions
- G70.0G70.2G73.1Myasthenia gravisCongenital and developmental myastheniaLambert-Eaton syndrome
- Registration Number
- DRKS00024099
- Lead Sponsor
- Deutsche Myasthenie Gesellschaft e.V.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 2000
Inclusion Criteria
ability to give consent
- diagnosis of MG, LEMS, CMS
Exclusion Criteria
Revocation of participation in the study
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary goal is to improve the quality of care in terms of quality assurance.<br>Relevant data for the treatment of myasthenia patients should be recorded and evaluated on the web. These data are to be used to research the care of patients with myasthenic syndromes and in particular to identify modifiable, previously unknown influencing factors on the long-term course in order to improve the treatment of the patients and thus also the long-term outcome of patients with myasthenia gravis (MG) To improve Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndrome (CMS).
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie treatment responses in DRKS00024099 Mya-Reg myasthenia gravis patients?
How does Mya-Reg observational data compare with standard-of-care outcomes for Lambert-Eaton syndrome?
Which biomarkers correlate with clinical outcomes in congenital myasthenia gravis registry studies?
What adverse event profiles are reported in myasthenic syndrome treatment registries like Mya-Reg?
Are there emerging therapies or drug combinations showing promise for myasthenia gravis beyond Mya-Reg data?